This Centrus Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiated coverage on CI (In-Line, $290), LEU (Overweight, $130), YARW (Buy, $40), SGHC (Equal-Weight, $13) and OFG (Sell, $50).
Last updated: 2026-11-19 07:02:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Yarrow Bioscience, Inc. (YARW) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $14.34, with a market capitalization of $216.49M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.39 to $44.28. This page covers its latest market performance, valuation, price trends and company information.
$216.49M | |
$14.41 | |
$15.69 | |
$14.14 | |
$14.21 | |
165.14K | |
151.89K | |
-- | |
$44.28 | |
$12.39 | |
-- | |
2026-06-30 |
Yarrow Bioscience, Inc. (YARW) last closed at $14.34 as of 2026-11-19 00:31:00, down 0.56% ($0.08) from the previous close of $14.21.
During the latest regular trading session, YARW traded between $14.14 and $15.69, with a volume of 165.14K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Yarrow Bioscience, Inc. (YARW) moved from $15.48 to $14.34, representing a decline of 7.34% ($1.14).
The stock traded between $13.53 and $19.92 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 155.20 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6.1%
YARW is currently trading at $14.34, placing it 6.1% of the way from its 52-week low of $12.39 to its 52-week high of $44.28. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Yarrow Bioscience, Inc. and YARW stock.
Analysts initiated coverage on CI (In-Line, $290), LEU (Overweight, $130), YARW (Buy, $40), SGHC (Equal-Weight, $13) and OFG (Sell, $50).
Jefferies analyst Faisal Khurshid initiates coverage on Yarrow Bioscience (NASDAQ:YARW) with a Buy rating and announces Price Target of $40.
Yarrow Bioscience (NASDAQ:YARW) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.32) by 34.37 percent.
Eligible investors can buy real shares of Yarrow Bioscience, Inc. (YARW) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to YARW, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between YARW shares and USD.
YARW Shares to USD
1.00 YARW shares = 14.343 USD
Calculations are estimates based on the latest available price and are for reference only.